ilomastat has been researched along with 3-nitrotyrosine in 1 studies
| Studies (ilomastat) | Trials (ilomastat) | Recent Studies (post-2010) (ilomastat) | Studies (3-nitrotyrosine) | Trials (3-nitrotyrosine) | Recent Studies (post-2010) (3-nitrotyrosine) |
|---|---|---|---|---|---|
| 103 | 0 | 45 | 3,510 | 87 | 1,137 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bencsik, P; Csonka, C; Ferdinandy, P; Giricz, Z; Lalu, MM; Schulz, R | 1 |
1 other study(ies) available for ilomastat and 3-nitrotyrosine
| Article | Year |
|---|---|
Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
Topics: Animals; Blotting, Western; Cholesterol, Dietary; Diet; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hydroxamic Acids; Hyperlipidemias; Indoles; Ischemic Preconditioning, Myocardial; L-Lactate Dehydrogenase; Male; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Myocardium; Protease Inhibitors; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Tyrosine | 2006 |